NCT04879056

Brief Summary

This study is designed to evaluate the instrument precision of the device for its proposed intended use in sub-studies: intra-system and inter-system. The precision within a system will be evaluated on three systems by three pathologists at one site. Specific features will be selected on glass slides, which will then be scanned. On the whole slide images field of views will be created including the features. In the reading phase three pathologists will read the field of views and record which features they observe.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
399

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 25, 2021

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 10, 2021

Completed
10 days until next milestone

Study Start

First participant enrolled

May 20, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2022

Completed
Last Updated

May 19, 2022

Status Verified

May 1, 2022

Enrollment Period

1.3 years

First QC Date

January 25, 2021

Last Update Submit

May 12, 2022

Conditions

Keywords

WSIfeatures

Outcome Measures

Primary Outcomes (1)

  • Presence or absence of features

    Each reading pathologist will record the presence of listed features on the checklist. The results will be used for deriving an agreement rate between repeated readings from the same reading pathologist over all enrolled (i.e. selected and validated) features.

    1 day

Study Arms (2)

intra-system

reviewing selected features on images from three iterations of the same scanner.

Diagnostic Test: PIPS 5.1

inter-system

reviewing selected features on images from three different scanners.

Diagnostic Test: PIPS 5.1

Interventions

PIPS 5.1DIAGNOSTIC_TEST

Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.

inter-systemintra-system

Eligibility Criteria

Age1 Year+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Study features are selected on glass slides from consecutive cases from the laboratory information system.

You may qualify if:

  • Left-over specimens from subjects who already received their diagnosis and have received their treatment in accordance with the standard of care
  • H\&E glass coverslipped slides with human tissue obtained via surgical pathology
  • Selected slides fulfill the quality checks according to the IfU
  • Selected slides must be at least one year since accessioning
  • Selected slides and FOVs must contain a study feature that is:
  • In it's natural environment (on slide and FOV)
  • Not equivocal (on slide and FOV)-

You may not qualify if:

  • Selected slides contain indelible markings
  • Selected slides contain damaged tissue
  • More than one slide was selected for a patient (only one slide may be enrolled per patient).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Capital Choice Pathology Laboratory

Silver Spring, Maryland, 20904, United States

RECRUITING

Study Officials

  • Mischa Nelis, MsC

    Philips Digital & Computational Pathology

    STUDY DIRECTOR

Central Study Contacts

Desiree van Neerven, MsC

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 25, 2021

First Posted

May 10, 2021

Study Start

May 20, 2021

Primary Completion

August 20, 2022

Study Completion

September 20, 2022

Last Updated

May 19, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations